Clinical trial NCT04456439: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Official title: Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Study type: EXPANDED_ACCESS
Overall status: AVAILABLE
Conditions: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Keywords: MIS-C
COVID-19
MSC
remestemcel-L
Mesoblast
mesenchymal
cellular therapy
cells
Lead sponsor: Mesoblast, Ltd.
Sponsor class: INDUSTRY
First posted: 2020-07-02
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD

Brief summary: The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.

Detailed description: This intermediate-size expanded access protocol plans to treat approximately 50 children or adolescents, male and female, with MIS-C associated with COVID-19. Participants who are 2 months to 17 years of age, inclusive, will be enrolled at multiple clinical sites across the United States.

Eligibility criteria: Inclusion Criteria

1. 2 months to 17 years of age, inclusive
2. Positive for current or recent SARS-CoV-2 (COVID-19) infection by real-time reverse transcription polymerase chain reaction (RT-PCR), serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms AND no alternative plausible diagnoses
3. Presenting with:

   * Fever (\>38.0°C or \>100.4°F for ≥24 hours) or reporting subjective fever lasting ≥24 hours
   * Laboratory evidence of inflammation with high sensitivity C-reactive protein (hsCRP) ≥4.0 milligrams per deciliter (mg/dL) and associated abnormalities of at least one of the following:

     * elevated erythrocyte sedimentation rate (ESR)
     * elevated fibrinogen
     * elevated procalcitonin
     * elevated d-dimer
     * elevated ferritin
     * elevated lactic dehydrogenase (LDH)
     * elevated interleukin 6 (IL-6)
     * elevated neutrophils
     * reduced lymphocytes
     * low albumin
   * Clinically severe multisystem illness requiring hospitalization with evidence for cardiac involvement plus at least one other organ involvement (renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)

     * Cardiac involvement is defined as reduced left ventricular ejection fraction (\<55%) in addition to at least one of the following:

       * increased troponin I,
       * increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) or BNP and/or
       * echocardiographic and/or other imaging evidence of left anterior descending coronary artery (LAD) and/or right coronary artery (RCA) dilation associated with a z-score \> 2.5
4. If on mechanical ventilation or ECMO, ≤72 hours post initiation of the respiratory support device

Exclusion Criteria

1. Documented other microbial cause for MIS-C including bacterial sepsis, staphylococcal or streptococcal shock syndromes, or infections associated with myocarditis such as enterovirus. Of importance, waiting for results of these investigations should not delay initiation of remestemcel-L therapy.
2. Females who are pregnant or lactating
3. Body mass index (BMI) ≥40 kilograms per square meter (kg/m\^2)
4. Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins
5. Aspartate aminotransferase/alanine transaminase (AST/ALT) ≥5x upper limit of normal (ULN)
6. Creatinine clearance \<30 mL/min
7. Serum creatinine \>2 mg/dL
8. Any end-stage organ disease which in the opinion of the treating physician may possibly affect the safety of the remestemcel-L treatment.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Mesoblast, Inc.
name: Kenneth M. Borow, MD
role: STUDY_DIRECTOR
References:
citation: Eckard AR, Borow KM, Mack EH, Burke E, Atz AM. Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children. Pediatrics. 2021 May;147(5):e2020046573. doi: 10.1542/peds.2020-046573. Epub 2021 Feb 12.